Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Eli Lilly and Company
Age
18–65
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Healthy males or females, as determined by medical history and physical examination
Have a body mass index (BMI) of 19.0 to 35.0 kilograms per meter squared (kg/m²) inclusive, at the time of screening
You may not be if
Have participated, within the last 30 days, in a clinical study involving an Investigational Product (IP)
Have previously completed or withdrawn from this study or any other study investigating Lasmiditan, and have previously received Lasmiditan
Have clinically significant abnormality in the 12-lead ECG, including corrected QT interval (QTc) with Fridericia's correction (QTcF) greater than (\>) 450 milliseconds (ms) for men or \>470 ms for women or any abnormality that in the opinion of the investigator increases the risk of participating in the study (not limited to significant bradycardia or heart block)
History of, show evidence of, or are undergoing treatment for significant active neuropsychiatric disease (for example, manic depressive illness, schizophrenia, depression), have a recent history of a suicide attempt (30 days within screening visit and any time between screening visit and baseline); or are clinically judged by the investigator to be at risk for suicide
History of hypoglycemia
Known history of glucose-6-phosphate dehydrogenase deficiency
Are taking a concomitant medication or a dietary substance that affects cytochrome P450 (CYP)1A2, CYP2C9, and/or CYP3A isotypes within 14 days of screening
Clareo Health | A Study of Multiple Doses of Lasmiditan in Healthy Participants
